Shares of AbbVie Inc (NYSE:ABBV) ended Tuesday session in green amid volatile trading. The shares closed up +0.67 points or 1.20% at $56.45 with 9.80 million shares getting traded. Post opening the session at $56.00, the shares hit an intraday low of $55.68 and an intraday high of $56.61 and the price vacillated in this range throughout the day. The company has a market cap of $89.03 billion and the numbers of outstanding shares have been calculated to be 1.63 billion shares.
AbbVie Inc (ABBV) develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Shares of Medtronic PLC (NYSE:MDT) ended Tuesday session in red amid volatile trading. The shares closed down -1.10 points or -1.34% at $80.92 with 5.66 million shares getting traded. Post opening the session at $82.02, the shares hit an intraday low of $80.45 and an intraday high of $82.40 and the price vacillated in this range throughout the day. The company has a market cap of $111.83 billion and the numbers of outstanding shares have been calculated to be 1.38 billion shares.
Medtronic PLC (MDT) manufactures and sells device-based medical therapies worldwide. The companys Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular intervention products, and products to treat superficial and deep venous diseases.